U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07549256) titled 'Cannabidiol for Pain Relief of Patients With End-stage mCRPC' on April 10.
Brief Summary: The goal of this clinical trial is to evaluate the effects of cannabidiol in patients with end-stage metastatic castration-resistant prostate cancer (mCRPC).
The primary objective is to determine whether cannabidiol (CBD) treatment can reduce the need for opioids in patients with end-stage mCRPC.
Additionally, the study will assess a range of clinical endpoints in patients with end-stage mCRPC, including:
1. The efficacy of CBD treatment in alleviating pain
2. The efficacy of CBD treatment in reducing the need for non-opioid medications an...